Want to learn more about careers in the STD field? To know the secrets to academic promotion? How to use social media in your professional life? Now is your chance to Ask an Expert! ASTDA is proud to sponsor the Ask an Expert breakfast session at the 2023 STI/HIV World Congress on Tuesday, July 25th from 7:00-8:00 am CT.   During the session, you will have the opportunity to participate in a small group, informal discussion with an expert in our field around a specific topic. To ensure the ability to have meaningful discussions, space is limited and registration is required with preference given to participants early in their career (i.e., not more than seven years from completion of training). If you are interested in participating, please complete this registration  form: https://www.surveymonkey.com/r/ASTDABreakfastRegistration

Organizer: Emma Harding-Esch
Moderators: Catherine Mathews and Emma Harding-Esch

• SP1.1 How to maximize potential of point-of-care tests & decentralized testing – Teodora Wi
• SP1.2 How much can automated care replace clinicians? – Claudia Estcourt
• SP1.3 Social innovation and STI care – Joe Tucker
• Panel Discussion

Organizer: Magnus Unemo
Moderators: Tania Crucitti and Magnus Unemo

• SY2.1 STI treatment options are running out – Magnus Unemo
• SY2.2 Molecular resistance testing and resistance-guided STI therapy: when and how to use – Catriona Bradshaw
• SY2.3 Future treatments for STIs – Lindley Barbee
• SY2.4 Doxycycline PrEP and PEP – impact on microbiome and antimicrobial resistance – Fabian Kong
• SY2.5 Optimizing STI treatment using pharmacodynamics – Magnus Unemo

• SY3.1 State of syphilis vaccine development – Lorenzo Giacani
• SY3.2 State of vaccine development for Neisseria gonorrhoeae – Sanjay Ram
• SY3.3 State of chlamydia vaccine development – Alvaro Borges
• SY3.4 STI vaccine acceptance and equity – Alison Footman

Moderators: Janneka Van de Wijgert and Hillary Reno

• O1.1 Bacterial Vaginosis and Spontaneous Clearance of Urogenital Chlamydia trachomatis in the Longitudinal Study of Vaginal Flora – Sarah Brown
• O1.2 The contribution of the vaginal microbiota to treatment failure following first-line antibiotics for bacterial vaginosis – Erica Plummer
• O1.3 Increasing rates of non-albicans Candida species and fluconazole resistant Candida albicans in women with recurrent vulvovaginal candidiasis in a UK region – Jennifer Ratner
• O1.4 Sexual transmission of urogenital bacteria in heterosexual partners: whole metagenome sequencing evidence from a sexual network study – Kayla Carter
• O1.5 Secreted Proteases from Bacterial Vaginosis-Associated Bacteria Target Human MMP-8 and Modulate Endocervical Barrier Function – Karen Lithgow
• O1.6 Spontaneous resolution and treatment outcomes in men with Trichomonas vaginalis infection – Christina Muzny

Moderators: Jane Rowley & Susan Tuddenham

• O3.1 Evaluating the clinical features of reported breakthrough cases of congenital syphilis — United States, 2016–2020 – Kevin O’Callaghan
• O3.2 Rates of reported primary and secondary syphilis among men who have sex with men compared to men who have sex with women only and women who have sex with men in 37 US states, 2018 – Jeremy Grey
• O3.3 Detection of Treponema pallidum at asymptomatic oral, anal and vaginal sites in men and women reporting contact with syphilis. – Ei Aung
• O3.4 Evolutionary insights into syphilis epidemiology – applying Treponema pallidum genomics in high- and low-income settings- Mathew Beale
• O3.5 Temporal Trends in HIV Status by Race/Ethnicity Among Reported Primary and Secondary Syphilis Cases Among Gay, Bisexual, and Other Men who have sex with Men — United States, 2011–2020 – Sarah Wondmeneh
• O3.6 Rapid Plasma Reagin (RPR) sero-reversion after treatment and its association with Prior Treponema Pallidum infection: analysis from the PICASSO cohort among people with early syphilis in Peru –Michael Reyes-Diaz

Moderators: Bill Miller and Charlie Peterson

• O5.1 PrEP Method Preferences and Anticipated Stigma Among Female, Male, and Transgender Sex Workers in India – Anne Fehrenbacher
• O5.2 THE ACCEPTABILITY OF PHARMACY-DELIVERED PREP IN KENYA: PROVIDER AND CLIENT PERCEPTIONS – Magdaline Asewe
• O5.3 Concordance between self-reported PrEP use using a diary app and intracellular tenofovir diphosphate in the Amsterdam PrEP demonstration project – Eline Wijstma
• O5.4 Age patterns of HSV-2 incidence and prevalence in two communities in Rakai, Uganda: a catalytic incidence model applied to population-based seroprevalence data – Lilith Whittles
• O5.5 Pritelivir for the treatment of resistant HSV infections in immunocompromised patients: update on an ongoing Phase 3 trial and Early Access Program – Alexander Birkmann
• O5.6 Knowledge and acceptability of Human Papillomavirus vaccination for young adult women in rural Mysore District, India: a qualitative study – Kate Coursey